NCT01961726View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Ischemic Heart Failure
Interventions
BIOLOGICAL

Placebo

Coronary Sinus Delivery

BIOLOGICAL

30 mg dose of JVS-100

Coronary Sinus Delivery

BIOLOGICAL

45 mg dose of JVS-100

Coronary Sinus Delivery

Trial Locations (4)

35211

Cardiology, P.C., Birmingham

45219

The Carl and Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati

84132

University of Utah, Salt Lake City

32610-0277

University of Florida, Gainsville

Sponsors
All Listed Sponsors
lead

Juventas Therapeutics, Inc.

INDUSTRY